Zacks Small Cap Has Pessimistic View of ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) – Analysts at Zacks Small Cap dropped their FY2025 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, September 2nd. Zacks Small Cap analyst D. Bautz now forecasts that the biotechnology company will post earnings per share of ($0.07) for […]

Leave a Reply

Your email address will not be published.

Previous post Brokers Set Expectations for Inventiva FY2025 Earnings
Next post essensys’ (ESYS) Buy Rating Reiterated at Canaccord Genuity Group